ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

19,646Medicare Part D Prescriptions Filled, Including Refills

Rank: 6 out of 1442

$1.35M Total Retail Price of All Prescriptions

Rank: 9 out of 1442

1,020 Patients Receiving at Least One Drug in Part D
98%Patients 65 Years and Older
94% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

0% of this provider’s 19,223 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

54% of this provider’s prescriptions were for brand-name drugs, compared to an average of 31%.

Prescription Price

$69 was the average price of a prescription from this provider, compared to $75 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
METOPROLOL SUCCINATE 1,525 1,498 1 1
AMLODIPINE BESYLATE 1,394 1,375 2 3
CARVEDILOL 1,022 1,007 3 8
DIOVAN 833 816 4 19
FUROSEMIDE 792 775 5 5
PLAVIX 703 668 6 14
CRESTOR 640 611 7 10
RANEXA 541 538 8 29
METOPROLOL TARTRATE 541 527 8 6
DIGOXIN 480 476 10 15
ATORVASTATIN CALCIUM 467 463 11 4
SIMVASTATIN 448 423 12 2
SPIRONOLACTONE 440 431 13 28
LIPITOR 433 432 14 24
DILTIAZEM 24HR CD 385 385 10 15 59
RAMIPRIL 379 376 16 18
POTASSIUM CHLORIDE 369 369 17 33
BENICAR 305 305 18 61
DOXAZOSIN MESYLATE 296 295 19 69
ZETIA 279 238 20 31
AMIODARONE HCL 277 277 21 49
ENALAPRIL MALEATE 273 244 22 23
CLOPIDOGREL 264 258 23 12
DEXILANT 261 256 24 160
HYDROCHLOROTHIAZIDE 257 253 25 16
BYSTOLIC 257 257 25 32
WARFARIN SODIUM 234 234 27 9
LOSARTAN POTASSIUM 233 233 28 13
TEKTURNA 218 218 29 131
PRAVASTATIN SODIUM 213 207 30 20
ISOSORBIDE MONONITRATE ER 211 211 31 17
COUMADIN 201 201 32 41
CLONIDINE HCL 198 198 33 66
DILTIAZEM HCL 191 191 34 159
DIOVAN HCT 190 190 35 35
MULTAQ 178 178 36 89
EPLERENONE 164 156 10 37 141
TOPROL XL 155 152 38 51
LOVAZA 152 134 39 37
ATENOLOL 148 148 40 11
TRILIPIX 145 145 41 104
SYNTHROID 144 133 42 40
PRADAXA 143 141 43 27
BENICAR HCT 133 133 44 86
DILTIAZEM 24HR ER 126 126 45 36
NEXIUM 121 121 46 34
NIASPAN 116 114 47 57
TRICOR 100 91 48 100
CARTIA XT 96 92 49 181
VYTORIN 94 94 50 101
HYDRALAZINE HCL 87 87 51 48
LISINOPRIL 85 85 52 7
RANITIDINE HCL 75 74 53 64
WELCHOL 69 56 54 143
LEVOTHYROXINE SODIUM 69 69 54 22
CAPTOPRIL 69 69 54 223
PROPRANOLOL HCL 58 58 57 116
LOSARTAN-HYDROCHLOROTHIAZIDE 54 54 58 30
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 9, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.